MedTrace Logo

Efficacy and Safety of THR-4109 in Obese Subjects

NCT00485017 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2019-09-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effect of THR-4109 on weight loss in obese subjects over a 24-week treatment period.

Conditions

Interventions

DRUG

THR-4109

THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks

DRUG

Placebo

Oral capsules daily in a.m. and in p.m. for 24 weeks

Sponsors & Collaborators

  • TFS Trial Form Support

    collaborator INDUSTRY

  • Theracos

    lead INDUSTRY

Principal Investigators

  • Natalie J Warner, MD · Theracos, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Russia
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00485017 on ClinicalTrials.gov